STANDARD OPERATING PROCEDURE SOP 720 RISK ASSESSMENT OF TRIALS SPONSORED. BY THE NNUH and UEA
|
|
- Evangeline Francis
- 5 years ago
- Views:
Transcription
1 STANDARD OPERATING PROCEDURE SOP 720 RISK ASSESSMENT OF TRIALS SPONSORED BY THE NNUH and UEA Version 1.0 Version date Effective date Number of pages 11 pages Review date November 2018 Author NNUH UEA Joint Research Office Approved by Lisa Chalkley Role Research Services Manger Signature Lisa Chalkley Date Authorised by Prof Alastair Forbes Role Chief of Research and Innovation Signature Prof Alastair Forbes Date SOP 720 v1.0 Effective date: Page 1 of 11
2 It is the responsibility of all users of this SOP to ensure that the correct version is being used. All staff should regularly check the NNUH R&D website for information relating to the implementation of new or revised versions of SOPs. Staff must ensure that they are adequately trained in the new procedure and must make sure that all copies of superseded versions are promptly withdrawn from use. The definitive versions of all Joint NNUH/UEA health care research SOPs appear online. If you are reading this in printed form please check that the version number and effective date is the most recent one as shown on the NNUH R&D website. TABLE OF CONTENTS 1 ABBREVIATIONS 3 2 INTRODUCTION 3 3 SCOPE 4 4 DEFINITIONS 4 5 RESPONSIBILITY 5 6 PROCEDURE Risk Assessment Acceptable Limits Which Risk Assessment is required? Completing the Risk Assessment a) NNUH Sponsored CTIMPs Studies b) All other NNUH Sponsored Studies c) UEA Sponsored Studies Risk Assessment Review 8 7 REFERENCES 8 8 RELATED DOCUMENTS 9 9 LIST OF APPENDICES 9 Appendix 1: Flow chart of Responsibilities 10 Appendix 2: Change Control, Revision and Review Sheet 11 SOP 720 v1.0 Effective date: Page 2 of 11
3 1 ABBREVIATIONS AE CE CI CMD CTIMP CTM ecrf EDC EU GCP ICH-GCP IMP ISO MHRA MP MTD NHS NNUH PI R&D ReDA RF RGC RSM SDV SmPC SOP SUSAR TMF UK Adverse Event Conformité Européene Chief Investigator Clinical Investigation of Medical Device Clinical Trial of Investigational Medicinal Product Clinical Trial Monitor Electronic Case Report Form Electronic Data Capture European Union Good Clinical Practice International Conference on Harmonisation Guidelines for Good Clinical Practice Investigational Medicinal Product International Organization for Standardization Medicines and Healthcare products Regulatory Agency Monitoring Plan Maximum Tolerated Dose National Health Service Norfolk and Norwich University Hospitals Principal Investigator Research and Development Research Database Application Research Facilitator Research Governance Coordinator Research Services Manager Source Data Verification Summary of Product Characteristics Standard Operating Procedure Suspected Unexpected Serious Adverse Reaction Trial Master File United Kingdom 2 INTRODUCTION Sponsors are required to provide oversight of studies to ensure adequate protection of the participants, sponsor and data integrity; however conducting research carries inherent risks. The purpose of a risk assessment is to identify potential hazards and assess the likelihood of those hazards occurring and resulting in harm. Dependent on the risks of a study, alternative/proportionate monitoring may be considered when developing monitoring strategies. The Medicines for Human Use (Clinical Trials) Regulations 2004 allow for riskadapted approaches to the management of clinical trials of investigational SOP 720 v1.0 Effective date: Page 3 of 11
4 medicinal products (CTIMPs). Norfolk and Norwich University Hospitals NHS Trust (NNUH) has adopted the risk-adaptive approach for the management of all studies it sponsors, including CTIMPs, clinical investigations of medical devices and all other research. 3 SCOPE This SOP applies to all healthcare research sponsored by NNUH and UEA which falls within the scope of the Research Governance Framework (2nd edition 2005) or its successor. Where additional legislation applies, for example the Medicines for Human Use (Clinical Trials) Regulations 2004 (and amendments) or the Medical Devices Regulations 2002, required procedures will be indicated. It is the responsibility of the local PI to ensure that studyspecific SOPs can be operated without conflicting with this SOP and in accordance with all organisational polices related to research. 4 DEFINITIONS CE Low Risk Likelihood Medium Risk Likelihood High Risk Likelihood "Conformité Européene" which literally means "European Conformity". The CE mark is required for all new products which are subject to one or more of the European product safety Directives. It is a visible sign that the manufacturer of the product is declaring conformity with all of the Directives relating to that product. Likely to be safe or without problem. Documentation and relevant experience / training in place. Concern of a possible effect on safety and/or possible problem arising, but evidence presented to address possible safety issues / problems. Majority of essential documentation and training in place with evidence of a plan to acquire missing documentation / training in place. Issues identified regarding safety and or problems arising, with no evidence presented to address safety issues / problems. Essential Documentation missing with no plan in place for acquiring documents. Evidence of relevant experience and/or training not demonstrated / documented, or with no plan in place to acquire necessary training / experience 5 RESPONSIBILITY Sponsor (fulfilled by the Research and Development (R&D) department on behalf of NNUH). Depending on the type of research being undertaken either the Research Facilitator (RF) or the Clinical Trial Monitor (CTM) will facilitate completion of the risk assessment and schedule attendees for the risk SOP 720 v1.0 Effective date: Page 4 of 11
5 assessment meeting, as required. Refer to flow chart in Appendix 1 for responsibility. The final decision to Sponsor a Trial will be made once the final signed Risk Assessment has been reviewed by the Research Services Manager (RSM). The CTM and/or RF or Research Governance Co-ordinator (RGC) or Research Services Manager (RSM) will implement the monitoring plan (MP) based on the outcome of the risk assessment. Chief Investigator (CI) To meet with RF and/or CTM for an initial Sponsored Risk Assessment meeting and complete any required follow-up actions. 6 PROCEDURES 6.1 Risk Assessment The risk assessment is based on identifying the potential hazards associated with the trial and assessing the likelihood of those hazards occurring and resulting in harm. Appropriate management/mitigation strategies should then be identified and implemented to bring any harm within an acceptable limit. The risk assessment should be undertaken prior to Sponsorship approval for studies the Trust will potentially be sponsoring. For UEA Sponsored studies where the Norwich Clinical Trials Unit (NCTU) has been designated to have a level of involvement where it is necessary for a risk assessment to be conducted, the NCTU will use its own risk assessment tool and follow its own processes. However NNUH will still carry out a risk assessment in accordance with this SOP Acceptable Limits If any section is rated high risk, after mitigating factors have been taken into account, the study will not be accepted for sponsorship. Sponsorship will be reconsidered by the RSM and/or RGC once it has been demonstrated by the CI that appropriate mitigating factors have been implemented to reduce the likelihood of risk to at least a medium risk level. If any section is rated medium risk, after mitigating factors have been taken into account this will trigger a monitoring plan reflective of the level of risk; the monitoring plan will be reviewed and updated if the level of risk is reduced by subsequent mitigating actions. If the overall outcome of the risk assessment is low the monitoring plan will be reflective of this level of risk; the monitoring plan will be reviewed and updated if the level of risk alters during the study. Refer to SOP 330 Monitoring for further details Which Risk Assessment is required? If it is unclear whether NNUH is the potential study Sponsor or Host, the RF or CTM should discuss with the RSM prior to conducting the risk assessment. SOP 720 v1.0 Effective date: Page 5 of 11
6 If NNUH is the potential host for a study please refer to R&D SOP_725 Capacity Capability and Risk Assessment of Trials Hosted by NNUH. If it is unclear what type of research is being undertaken (i.e. is it a clinical trial?) the RF or CTM or CI should seek to clarify this - if necessary by contacting the Medicines and Healthcare products Regulatory Agency (MHRA). The RF or CTM will co-ordinate the risk assessment depending on the type of research being conducted (see 6.1.4) and Appendix 1 for guidance. If, during the risk assessment meeting, risks are identified which are not appropriately managed/mitigated by the CI and study team, the RF or CTM will liaise with the RSM or RGC as soon as possible, the RSM and/or RGC will decide appropriate action. If risks are not satisfactorily managed/mitigated this may affect study set-up activity and the study could be put on hold Completing the Risk Assessment a) NNUH Sponsored CTIMP Studies Prior to Sponsorship approval, the RF will contact the CI and arrange a meeting with them and the study team. It may be possible for the RF to complete parts of the NNUH Sponsored Risk Assessment Tool prior to the meeting based on the study information available to them already (e.g. Protocol). The RF will meet with the CI and study team and conduct the NNUH Sponsored risk assessment. The RF should then complete any section that could not be done prior to the meeting. Where an NNUH Sponsored study has significant UEA involvement the RF should notify the relevant REN Project Officer of the risk assessment meeting. In some instances where it is felt that the risk assessment meeting would benefit from UEA REN involvement, the relevant UEA REN project officer will also attend the risk assessment meeting. Once finalised the Risk Assessment Tool should be sent by the RF to the CI to review, sign and return. The RF should then countersign the Risk Assessment Tool. In all instances where an NNUH Sponsored study has significant UEA involvement a copy of the final Risk Assessment Tool should be sent to the UEA REN project officer who was notified of the risk assessment meeting. The summary table of risk at the end of the tool should only be completed with the level of risk recorded for each section and sub-section. Any actions resulting from the risk assessment meeting should be entered into the table at the end of the tool; completion of the actions can take place after the NNUH Sponsored Risk Assessment Tool has been finalised. The RSM and/or RGC will be notified by the RF once the NNUH Sponsored Risk Assessment has been completed and a copy of the fully executed Risk Assessment Tool sent to them and to the CI. SOP 720 v1.0 Effective date: Page 6 of 11
7 The Sponsorship Review letter, containing the official decision regarding sponsorship will be sent to the CI by the RSM, following completion of the risk assessment. Risk assessment documentation should be saved electronically in the projects shared folder, documented in ReDA, and filed in the sponsor trial master file (TMF). For NNUH Sponsored CTIMP Studies where NNUH has retained monitoring responsibilities the RF and NNUH Clinical Trial Monitor should work together to complete all steps mentioned in a, with the Clinical Trial Monitor taking overall responsibility for the completion of the risk assessment b) All other NNUH Sponsored Studies Prior to Sponsorship approval the RF will contact the CI and arrange a meeting with them, and the study team. It may be possible for the RF to complete parts of the NNUH Sponsored Risk Assessment Tool prior to the meeting based on the study information available to them already (e.g. Protocol). The RF will meet with the CI and study team and conduct the NNUH Sponsored risk assessment. The RF should then complete any section that could not be done prior to the meeting. Where an NNUH Sponsored study has significant UEA involvement the RF should notify the relevant REN Project Officer of the risk assessment meeting. In some instances where it is felt that the risk assessment meeting would benefit from UEA REN involvement the relevant UEA REN project officer will also attend the risk assessment meeting. Once finalised the Risk Assessment Tool should be sent by the RF to the CI to review, sign and return. The RF should then countersign the Risk Assessment Tool. In all instances where an NNUH Sponsored study has significant UEA involvement a copy of the final Risk Assessment Tool should be sent to the UEA REN project officer who was notified of the risk assessment meeting. The summary table of risk at the end of the tool should only be completed with the level of risk recorded for each section and sub-section. Any actions resulting from the risk assessment meeting should be entered into the table at the end of the tool; completion of the actions can take place after the NNUH Sponsored Risk Assessment Tool has been finalised. The RSM or RGC will be notified by the RF once the NNUH Sponsored Risk Assessment has been completed, and a copy of the fully executed Risk Assessment Tool has been sent to the CI. The Sponsorship Review letter, containing the official decision regarding sponsorship will be sent to the CI by the RSM, following completion of the risk assessment. SOP 720 v1.0 Effective date: Page 7 of 11
8 Risk assessment documentation should be saved electronically in the projects shared folder, documented in ReDA, and filed in the sponsor trial master file (TMF) c) UEA Sponsored Studies Sponsorship approval at both the application and award stages includes risk assessment following the REN Processes and Guidance Notes. Where the studies are adopted by the NCTU, additional risk assessments are undertaken as per NCTU processes and risk assessment tool. 6.2 Risk Assessment Review The risk assessment may be reviewed at any time during the study, taking into account new knowledge and experience, and may include reconsiderations of the acceptable limit of risks (refer to 6.1.2). This may occur as a result of any of the following (this list is not exhaustive): i. Monitoring findings; ii. Audit or inspection outcome; iii. Safety review; iv. Serious breach or non-compliance; v. Change to protocol, resources, personnel, facilities or external service providers. The risk assessment review will be completed as per It may not be necessary to revise all sections of the NNUH Sponsored Risk Assessment Tool, or to convene a meeting of all original members of the sponsor panel. The RF or CTM, RSM or RGC and CI will agree which sections will be revised and who should attend the review meeting. The RF or CTM will update the study Monitoring Plan accordingly, following the risk assessment review and will notify the CI. 7 REFERENCES ICH Harmonised Tripartite Guideline Quality Risk Management Q9: Current Step 4 version, 9 November 2005 MRC/DH/MHRA Joint Project Risk-adapted Approaches to the Management of Clinical Trials of Investigational Medicinal Products: version 10 October 2011 The Medicines for Human Use (Clinical Trials) Regulations 2004 Medical Devices Regulations 2002 The MHRA Good Clinical Practice Guide 2012 Research Governance Framework (2nd edition 2005). Nottingham University Hospitals SOP-RES-002 Risk Assessment SOP 720 v1.0 Effective date: Page 8 of 11
9 8 RELATED DOCUMENTS Joint Arrangements for Research NNUH Sponsored Risk Assessment Tool R&D SOP_725 Capacity Capability and Risk Assessment of Trials Hosted by NNUH R&D SOP_330 Monitoring Clinical Trials Sponsorship Review Letter REN Processes & Guidance Notes. B: Applications. C. Awards 9 LIST OF APPENDICES Appendix 1: Flow chart of Responsibilities Appendix 2: Change Control, Revision and Review Sheet SOP 720 v1.0 Effective date: Page 9 of 11
10 Appendix 1: Flow chart of Responsibilities Is this study a CTIMP? YES NNUH Sponsored Study Is the Study Sponsored by NNUH or UEA? NNUH UEA Clinincal Trial Monitor will work with Research Facilitator and CI to complete risk assessment. Research Facilitator will work wiith CI to complete risk assessment. Refer to REN Processes and Guidance Notes. B: Applicationa C. Awards - "Risk Assessment of Trials Sponosred by the NNUH and UEA" SOP to be followed - Sponsored Risk Assessment Tool to be completed - Research Service Manager or Research Governance Co-ordinator will be informed by Research Facilitiator or Clinical Trial Monitor when risk assessment has been completed What is the outcome of risk assessment? High Low Medium Study will not be accepted for Sponosrship. Sponsorship will be formally confirmed - Sponsorship will be reviewed by the Research Service Manager or Research Governance Coordinator once it has been demonstrated by the CI that appropriate actions have been implemented to reduce the likelihood of risk to at least a medium risk level. Once the risk has been reduced - Monitoring plan will be reflective of the risk for the study. - Risk assessment can be reviewed at any point of the study - Risk assessment documentation should be saved electronically in the projects shared folder, and documented in ReDA, and filed in the sponsor trial master file SOP 720 v1.0 Effective date: Page 10 of 11
11 Appendix 2: Change Control, Revision and Review Sheet CHANGE CONTROL, REVISION AND REVIEW SHEET: SOP 001 Version No Change Date Reason for Change Reviewer : Designation : Signature and Date: Reviewer : Designation : Signature and Date: SOP 720 v1.0 Effective date: Page 11 of 11
STANDARD OPERATING PROCEDURE
STANDARD OPERATING PROCEDURE Title Reference Number Site Initiation SOP-RES-010 Version Number 2 Issue Date 15 Apr 2016 Effective Date 26 May 2016 Review Date 26 May 2018 Author(s) Reviewer(s) Rachelle
More informationNEWCASTLE CLINICAL TRIALS UNIT STANDARD OPERATING PROCEDURES
SOP details SOP title: SOP number: SOP category: Version number: 03 Version date: 19 December 2016 Effective date: 19 January 2017 Revision due date: 19 January 2020 NEWCASTLE CLINICAL TRIALS UNIT STANDARD
More informationStandard Operating Procedure CPFT/SOP003 Serious Breach of Protocol or GCP in CTIMPs
Standard Operating Procedure CPFT/SOP003 Serious Breach of Protocol or GCP in CTIMPs Author: Sponsor/Executive: Responsible committee: Ratified by: Consultation & Approval: (Committee/Groups which signed
More informationSOP-QA-30 V Scope
Title: Effective Date: 1-4-17 Review Date: 1-4-20 Author: Joanne Rodger, Senior R&D Manager QA Approval: Richard Cowie, QA Manager Approver: Prof Maggie Cruickshank, R&D Director Approver: Prof Steve Heys,
More informationAnnual Progress and Safety Reporting SOP for HEY-sponsored CTIMPs
R&D Department Annual Progress and Safety Reporting SOP for HEY-sponsored CTIMPs Hull and East Yorkshire Hospitals NHS Trust 2010 All Rights Reserved No part of this document may be reproduced, stored
More informationStandard Operating Procedures (SOP) Research and Development Office
Standard Operating Procedures (SOP) Research and Development Office Title of SOP: GCP Inspection Procedures (MHRA) SOP Number: 15 Version Number: 2.0 Supercedes: 1.0 Effective date: August 2013 Review
More informationl Chief Investigator/R & D Committee member
North Staffordshire Combined Healthcare '~l:~j Breach of Protocol or Good Clinical Practice SOP Reference R&D-SOP-SOS-002 Version Number Effective Date 19'" February 2010 Review Date 18 m February 2012
More informationResearch & Development. J H Pacynko and J Illingworth. Research, pharmacy and R&D staff
Department Title of SOP Research & Development Safety reporting SOP SOP reference no: R&D GCP SOP 07 Authors: Current version number and date: J H Pacynko and J Illingworth Version 9, 31.01.18 Next review
More informationStandard Operating Procedure Research Governance
Queen s University Belfast Research and Enterprise Standard Operating Procedure Research Governance Title: Application to MHRA for Clinical Trials Authorisation SOP Reference QUB-ADRE-OlO Date prepared
More informationSTANDARD OPERATING PROCEDURE
Research Department STANDARD OPERATING PROCEDURE SOP Number C117 Version Number 1.3 Effective Date Author Anna Leesley Angela Pinder Related SOPs C108: Sponsorship C109: Code Break B131: Monitoring of
More informationSTANDARD OPERATING PROCEDURE
Research Department STANDARD OPERATING PROCEDURE SOP Number C117 Version Number 2.1 Effective Date 01 Sept 2018 Author Angela Pinder Related SOPs C108: Sponsorship C109: Code Break C118: Risk Assessment
More informationManaging the risks of clinical trials: the MRC/MHRA approach
Managing the risks of clinical trials: the MRC/MHRA approach Sarah Meredith MRC Clinical Trials Unit at UCL UCL Institute for Clinical Trials and Methodology FCRIN Workshop, Hôpital Saint Louis, Paris
More informationInformed Consent Procedures and Writing Informed Consent Forms
STANDARD OPERATING PROCEDURE Informed Consent Procedures and Writing Informed Consent Forms Standard Operating Procedure Western Health SOP reference 006 Version: 2.0 dated December 2015 Effective Date
More informationDATA MONITORING COMMITTEE & TRIAL STEERING COMMITTEE CHARTERS
DATA MONITORING COMMITTEE & TRIAL STEERING COMMITTEE CHARTERS DOCUMENT NO.: CR015 v1.0 AUTHOR: Lorn Mackenzie ISSUE DATE: 31 January 2017 EFFECTIVE DATE: 14 February 2017 1 INTRODUCTION 1.1 The Academic
More informationUNIVERSITY OF LEICESTER, UNIVERSITY OF LOUGHBOROUGH & UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST JOINT RESEARCH & DEVELOPMENT SUPPORT OFFICE
UNIVERSITY OF LEICESTER, UNIVERSITY OF LOUGHBOROUGH & UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST JOINT RESEARCH & DEVELOPMENT SUPPORT OFFICE STANDARD OPERATING PROCEDURES University of Leicester (UoL)
More informationStandard Operating Procedure. Selection of studies performed in compliance with Good Laboratory Practice for audit purposes
Scope To describe the procedure for EFSA to request on a yearly or ad-hoc basis the performance of GLP studies audits by the GLP Monitoring Authorities. To lay down criteria for the selection of the GLP
More informationStandard operating procedure
Standard operating procedure Title: Preparation of an initial European Public Assessment Report (EPAR) for a human medicinal product following positive or negative opinion Status: PUBLIC Document no.:
More informationControl of Substances Hazardous to Health (COSHH) Regulations 2002
Control of Substances Hazardous to Health (COSHH) Regulations 2002 1. Purpose This document provides guidance to staff on how to comply with the COSHH Regulations 2002 (as amended) and in particular informs
More informationMHRA Pharmacovigilance System Master File (PSMF) Inspection Findings
MHRA Pharmacovigilance System Master File (PSMF) Inspection Findings Gretel Sakyi Medical Information and Patient Safety Manager AstraZeneca UK 07 June 2018 Agenda MHRA inspections How inspectors use the
More informationTrust Policy 218 Ionising Radiation Safety Policy
Trust Policy 218 Ionising Radiation Safety Policy Purpose Date Version August 2016 7 To ensure that Plymouth Hospitals NHS Trust complies with all relevant legislation with regard to the use of ionising
More informationAdult Patient Information and Consent Form
The ROAM Trial Radiation versus Observation following surgical resection of Atypical Meningioma: a randomised controlled trial
More informationStandard operating procedure
Standard operating procedure Title: Early Notification System: procedure for advanced notification of emerging safety issues to EU regulatory network and international partners Status: PUBLIC Document
More informationDarwin Marine Supply Base HSEQ Quality Management Plan
Darwin Marine Supply Base HSEQ Quality Management Plan REVISION SUMMARY Revision Date Comment Authorised 0 29.9.13 Initial input JC 1 12.1.15 General Review JC 2 3 4 5 6 7 8 9 Revision Log Revision No
More informationOverview Internal review
Overview Internal review Presentation title: QRM, It s not all about the assessment Track title: Day 1, Session 2 Speaker: Seamus Orr Date / Time: 10 August 2015, 14.30 15.00 Time allotted: 30 minutes
More informationOnline Form. Welcome to the Integrated Research Application System. IRAS Project Filter
Welcome to the Integrated Research Application System IRAS Project Filter The integrated dataset required for your project will be created from the answers you give to the following questions. The system
More informationCutanea Life Sciences, Inc. Comprehensive Compliance Program
Cutanea Life Sciences, Inc. Comprehensive Compliance Program Cutanea engages in research, development, manufacture and marketing of dermatology products, including commercialization of those products.
More informationChanging practice to support service delivery
Nurse and Midwife Medicinal Product Prescribing Toolkit Authorised Medicinal Products, Off-label Prescription and Exempt Medicinal Products Toolkit Changing practice to support service delivery Introduction
More informationCOMPETENT AUTHORITY (UK) MEDICAL DEVICES DIRECTIVES GUIDANCE NOTES FOR MANUFACTURERS OF DENTAL APPLIANCES
COMPETENT AUTHORITY (UK) 10 EC MEDICAL DEVICES DIRECTIVES GUIDANCE NOTES FOR MANUFACTURERS OF DENTAL APPLIANCES (CUSTOM MADE DEVICES) Updated March 2008 CONTENTS PAGE Introduction 3 Definition of dental
More informationAUDIT TOOL FOR SELF INSPECTION OF COMPLIANCE WITH QUALITY MANAGEMENT SYSTEM FOR PATIENT GROUP DIRECTIONS
AUDIT TOOL FOR DISPENSING SERVICES COMPILED BY: Lynn Morrison ISSUE 1 CHECKED BY: Colette Byrne NUMBER: ISSUE DATE: 01.12.07 SUPERSEDES: NEW REVIEW DATE: 01.12.09 AUDIT TOOL FOR SELF INSPECTION OF COMPLIANCE
More informationNA LEVEL 3 TECHNICAL QUALIFICATION RECOGNITION
NA-019 - LEVEL 3 TECHNICAL QUALIFICATION RECOGNITION Introduction This procedure reflects the adoption of the EN4179-2014 wording as Australian Standard AS3669, and describes the NANDTB processes when
More informationNA-019 LEVEL 3 QUALIFICATION RECOGNITION FOR AS3669 AND EN 4179 / NAS 410
NA-019 LEVEL 3 QUALIFICATION RECOGNITION FOR AS3669 AND EN 4179 / NAS 410 Initial Qualification Recognition This procedure describes how the NANDTB recognises NDT Level 3 personnel qualifications as meeting
More informationIPC Athletics. Classification Rules and Regulations
I P C AT H L E T I C S IPC Athletics Classification Rules and Regulations September 2011 IPC ATHLETICS CLASSIFICATION RULES AND REGULATIONS The IPC Athletics Classification Rules and Regulations are integral
More informationPIC/S GUIDANCE ON CLASSIFICATION OF GMP DEFICIENCIES
PHARMACEUTICAL INSPECTION CONVENTION PHARMACEUTICAL INSPECTION CO-OPERATION SCHEME PI 040-1 3 Appendices 1 January 2019 PIC/S GUIDANCE ON CLASSIFICATION OF GMP DEFICIENCIES PIC/S January 2019 Reproduction
More informationGuideline on good pharmacovigilance practices (GVP)
19 April 2013 EMA/169546/2012 Guideline on good pharmacovigilance practices (GVP) Module X Additional monitoring Draft finalised by the Agency in collaboration with Member States 25 May 2012 Draft agreed
More informationTitle: Handling of a request for accelerated assessment of initial marketing authorisation applications (human use)
European Medicines Agency Standard Operating Procedure Title: Handling of a request for accelerated assessment of initial marketing authorisation applications (human use) PUBLIC Document no.: SOP/H/3182
More informationPolicy: S5 Smoke Free Policy
Policy: S5 Smoke Free Policy Version: S5/15 Ratified by: Trust Management Team Date ratified: 3 rd June 2015 Title of Author: Clinical Services Manager/Specialist & Forensic Title of responsible Executive
More informationIPC Athletics Classification Rules and Regulations
IPC Athletics Classification Rules and Regulations February 2013 International Paralympic Committee Adenauerallee 212-214 Tel. +49 228 2097-200 www.paralympic.org 53113 Bonn, Germany Fax +49 228 2097-209
More informationInformation Technology Solutions
Information Technology Solutions World Institute of Pain (WIP) Excellence in Pain Practice Award Award Applicant Site Inspection Handbook June 28, 2010 WIP EPP Award Site Inspection Handbook Page 2 Table
More informationStandard operating procedure
Standard operating procedure Title: Article 29(4) referral procedures (MRP/DCP referrals) Status: PUBLIC Document no.: SOP/H/3177 Lead author Approver Effective date: 04-SEP-12 Name: Thomas Larsson Name:
More informationONR GUIDE. The Role of the UK National Coordinators for International Operating Experience Report Systems. ONR-OPEX-GD-003 Revision 3
Title of document ONR GUIDE The Role of the UK National Coordinators for International Operating Experience Report Systems Document Type: Unique Document ID and Revision No: ONR Guide ONR-OPEX-GD-003 Revision
More informationMS Society Safeguarding Adults Policy and Procedure (Scotland)
MS Society Safeguarding Adults Policy and Procedure (Scotland) Safeguarding Adults Policy The phrase adult support and protection is used instead of safeguarding in Scotland. However for consistency across
More informationCARIBX (UK) LIMITED. Environmental, Health and Safety Management System. Revision: 00 APRIL 2011
CARIBX (UK) LIMITED Environmental, Health and Safety Management System Revision: 00 APRIL 2011 Document Details and Issue Record Rev No. Details Date Author Checked Text 00 Draft 01/04/2011 CJMD Calcs
More informationNewcastle Safeguarding Children Board Business Group Terms of Reference
Newcastle Safeguarding Children Board Business Group Terms of Reference 1. Purpose Newcastle Safeguarding Children Board (NSCB) Business Group will act as the executive business group on behalf of Newcastle
More informationManagement of AIDS/HIV Infected Healthcare Workers Policy
Management of AIDS/HIV Infected Healthcare Workers Policy DOCUMENT CONTROL: Version: 4 Ratified by: Corporate Policy Panel Date ratified: 20 July 2017 Name of originator/author: HR Manager Name of responsible
More informationNA-019 Level 3 Qualification Recognition for EN 4179 / NAS 410 and AS3669
NA-019 Level 3 Qualification Recognition for EN 4179 / NAS 410 and AS3669 This procedure describes how the NANDTB recognises NDT Level 3 personnel qualifications as meeting the requirements of EN 4179,
More informationTITLE: Obtaining Informed Consent of Non-English Speakers SOP #: CON-101 (formerly SM-507) Page: 1 of 7 Effective Date: 1/14/2016
SOP #: CON-101 (formerly SM-507) Page: 1 of 7 Effective Date: 1. POLICY STATEMENT: All informed consent information (initial or updates for new information) must be presented in a language that is understandable
More informationThe Nutrition (Amendment) (EU Exit) Regulations 2018
The Nutrition (Amendment) (EU Exit) Regulations 2018 A public consultation Contents Introduction... 3 Why we are consulting... 4 Nutrition and Health Claims... 6 Proposals... 6 Vitamins, minerals, and
More informationLEAF Marque Assurance Programme
Invisible ISEAL Code It is important that the integrity of the LEAF Marque Standard is upheld therefore the LEAF Marque Standards System has an Assurance Programme to ensure this. This document outlines
More informationSpecialist Research Ethics Guidance Paper RESEARCH INVOLVING ADULT PARTICIPANTS WHO LACK THE CAPACITY TO CONSENT
Specialist Research Ethics Guidance Paper RESEARCH INVOLVING ADULT PARTICIPANTS WHO LACK THE CAPACITY TO CONSENT This note covers all research undertaken at the University that involves the recruitment
More informationPatient Group Directions (PGDs)
Patient Group Directions (PGDs) Document level: Trustwide (TW) Code: MP2 Issue number: 4 Lead executive Authors details Type of document Target audience Document purpose Medical Director Senior Clinical
More informationKeep Fit Equipment Usage Policy and Procedure
Keep Fit Equipment Usage Policy and Procedure Reference No. P03:2005 Implementation date 1 January 2005 Version Number 1.5 Reference No: Name. Linked documents Policy Section Procedure Section Suitable
More informationGuide to Interchangeable Medicines
Guide to Interchangeable Medicines AUT-G0115-6 01 JUNE 2018 This guide does not purport to be an interpretation of law and/or regulations and is for guidance purposes only. CONTENTS 1 BACKGROUND 3 1.1
More informationPATIENT GROUP DIRECTIONS POLICY
PATIENT GROUP DIRECTIONS POLICY To be read in conjunction with the Medicines Policy and the Controlled Drugs Policy Version: 5 Ratified by: Senior Managers Operations Group Date ratified: August 2015 October
More informationBMA INFORMATION BULLETIN No. 23. International Safety Management (ISM) Code
BMA INFORMATION BULLETIN No. 23 International Safety Management (ISM) Code Guidance and instructions for Ship-owners, Managers, Masters, Bahamas Recognised Organisations and Bahamas Approved Inspectors
More informationALCOHOL & DRUG USE INCIDENT MANAGEMENT POLICY
ALCOHOL & DRUG USE INCIDENT MANAGEMENT POLICY 1. RATIONALE Drug use by students increases the risk of injury to the students themselves and to others, as well as impairing the ability of students to respond
More informationDeveloping a Research Protocol/Proposal
Developing a Research Protocol/Proposal Helen Neilens Research Advisor Plymouth Hospitals NHS Trust hneilens@nhs.net My Role To help researchers follow the research procedures and processes necessary to
More informationPROCEDURE Mental Capacity Act. Number: E 0503 Date Published: 20 January 2016
1.0 Summary of Changes This document has been redrafted and should be read in full by all officers and staff engaged in providing any response to the public concerning all aspects of Mental Health. This
More informationNO SMOKING POLICY POLICY IMPLEMENTATION CHECKLIST
NO SMOKING POLICY POLICY IMPLEMENTATION CHECKLIST Policy Guardian: Business Services Director Author: Business Performance Manager Version number: 1.0 Approved by Chief Executive on: 3 September 2013 Approved
More informationIonising Radiation Policy
Ionising Radiation Policy CONTENTS 1. University Policy. 2. Procedures / Guidance. 2.1 Responsibilities of the Deans of Schools and/or Heads of Departments 2.2 Radiation Protection Advisor / Radiation
More informationDivision of Research University Policy
Division of Research University Policy SUBJECT: Effective Date: Policy Number: SATELLITE ANIMAL HOUSING FACILITIES June 24, 2016 Supersedes: August 22, 2014 1 5 Responsible Authorities: Vice President,
More informationSchool Hearing Screening Policy
School Hearing Screening Policy V2.1 1st August 2017 Page 1 of 13 Table of Contents 1. Introduction... 3 2. Purpose of this Policy... 3 3. Scope... 3 4. Definitions / Glossary... 3 5. Ownership and Responsibilities...
More informationGOVERNING BODY MEETING in Public 22 February 2017 Agenda Item 3.4
GOVERNING BODY MEETING in Public 22 February 2017 Paper Title Purpose of paper Redesign of Services for Frail Older People in Eastern Cheshire To seek approval from Governing Body for the redesign of services
More informationPATIENT GROUP DIRECTION PROCEDURE
PATIENT GROUP DIRECTION PROCEDURE Date approved 2 October 2015 Version 3 Approved by Yvette Oade, Chief Medical Officer Procedure Lead Clinical Governance Lead - Medicines Management Procedure Author Karen
More informationAssessment of Mental Capacity and Best Interest Decisions
Standard Operating Procedure 1 (SOP 1) Assessment of Mental Capacity and Best Interest Decisions Why we have a procedure? This Standard Operating Procedure (SOP) is required to set out how a person s capacity
More informationPatient Group Directions Policy
Patient Group Directions Policy Category: Summary: Equality Analysis undertaken: Valid From: Date of Next Review: Approval Date/ Via: Distribution: Related Documents: Author(s): Further Information: This
More informationDay care and childminding: Guidance to the National Standards
raising standards improving lives Day care and childminding: Guidance to the National Standards Revisions to certain criteria October 2005 Reference no: 070116 Crown copyright 2005 Reference no: 070116
More informationGLP in the European Union Ecolabel detergents, GLP and accreditation
GLP in the European Union Ecolabel detergents, GLP and accreditation Maik Schmahl Brussels, 25/03/2010 Chemicals Unit Outline What is GLP? How has it developed? The role of the Member States, the European
More informationQuality Assurance Policy. for the. Procurement of HIV Point-of-Care Technology. under the UNITAID Grant
Quality Assurance Policy for the Procurement of HIV Point-of-Care Technology under the UNITAID Grant UNICEF Supply Division Quality Assurance Centre and Health Technology Centre Revisions Version Date
More informationEMEA PANDEMIC INFLUENZA CRISIS MANAGEMENT PLAN FOR THE EVALUATION AND MAINTENANCE OF PANDEMIC INFLUENZA VACCINES AND ANTIVIRALS
European Medicines Agency London, 21 August 2006 Doc. Ref. EMEA/214301/2006 EMEA PANDEMIC INFLUENZA CRISIS MANAGEMENT PLAN FOR THE EVALUATION AND MAINTENANCE OF PANDEMIC INFLUENZA VACCINES AND ANTIVIRALS
More informationA Case Study of Policy and Practice in Occupational Health. and Safety in South Australia. Grant Dewar
A Case Study of Policy and Practice in Occupational Health and Safety in South Australia Grant Dewar A dissertation submitted in partial fulfilment of the requirements for the degree of Master of Education
More informationDE-DESIGNATION OF YELLOW FEVER VACCINATION CENTRES
DE-DESIGNATION OF YELLOW FEVER VACCINATION CENTRES January 2014 INDEX Page 1. Introduction 3 2. De-designating a YFVC 4 3. The de-designation process 5-6 4. Repeated breaches of the standards for designation
More informationHuman Subject Institutional Review Board Proposal Form
FOR IRB USE ONLY Protocol Number: IRB- Human Subject Institutional Review Board Proposal Form Activity Title: PRINCIPAL INVESTIGATOR ASSURANCE I agree to use procedures with respect to safeguarding human
More informationCommitted to Environment, Health and Safety
Committed to Environment, Health and Safety Environment, Health and Safety Management System and Policy of GCP Applied Technologies Inc. SEPTEMBER 1, 2017 The GCP Environment, Health, and Safety Management
More informationStandard Operating Procedure:
Standard Operating Procedure: Name of procedure: Taking Informed Consent SOP Number: SOP07/UoE/HTA (includes Adverse Events Reporting Form) Version Number & Date: V5 16/01/2017 Review Date: Annually Superseded
More informationWHO Polio Eradication Programme UK National Survey of Polioviruses
E WHO Polio Eradication Programme UK National Survey of Polioviruses A Paper submitted to the Health and Safety Committee Meeting, 17 th April 2008, by Alastair Reid. In September 2001, the University
More informationClub administration and record keeping 90 Leadership and governance 315 Publicity and community engagement Club AGM Club Representation
Staffordshire County Federation of Young Farmers Clubs Club Efficiency Competition RULES and GUIDELINES Competition aim: The aim of the Staffordshire County Federation of Young Farmers Clubs (SCFYFC) Club
More informationCurrent European Experience with trial approval in early development : Afssaps (France)
Current European Experience with trial approval in early development : Afssaps (France) Dr Chantal Bélorgey Head, Clinical Trials and special status MP Department AGAH-Club Phase 1 28 April 2009 FIH in
More informationCommitted to Environment, Health, & Safety
Committed to Environment, Health, & Safety Environment, Health, and Safety Management System and Policy of W. R. Grace & Co. November 8, 2018 The Grace Environment, Health, and Safety Management System,
More informationCOMMISSION REGULATION (EU)
11.3.2011 Official Journal of the European Union L 64/15 COMMISSION REGULATION (EU) No 234/2011 of 10 March 2011 implementing Regulation (EC) No 1331/2008 of the European Parliament and of the Council
More informationEFSA PRE-SUBMISSION GUIDANCE FOR APPLICANTS INTENDING TO SUBMIT APPLICATIONS FOR AUTHORISATION OF HEALTH CLAIMS MADE ON FOODS
EFSA PRE-SUBMISSION GUIDANCE FOR APPLICANTS INTENDING TO SUBMIT APPLICATIONS FOR AUTHORISATION OF HEALTH CLAIMS MADE ON FOODS Last updated (Rev.): 21 December 2007 Publication Date: 14 March 2007 NOTES
More informationDeveloped By Name Signature Date
Patient Group Direction 2155 version 2.0 Administration / Supply of Inhaled Salbutamol in Asthma by Registered Practitioners employed by Torbay and South Devon NHS Foundation Trust Date of Introduction:
More informationPrEP Impact Trial: A Pragmatic Health Technology Assessment of PrEP and Implementation. Part 1
The Elton John Centre Sussex House 1 Abbey Road Brighton BN2 1ES Tel 01273 523079 Fax 01273 523080 PARTICIPANT INFORMATION SHEET AND CONSENT FORM PrEP Impact Trial: A Pragmatic Health Technology Assessment
More informationIn 2013, Her Majesty s Inspectorate of Constabularies published Stop and Search Powers: Are the police using them effectively and fairly?
STOP & SEARCH POWERS Are the police using them effectively and fairly? In 2013, Her Majesty s Inspectorate of Constabularies published Stop and Search Powers: Are the police using them effectively and
More informationLakshy Management Consultant Pvt. Ltd.
What is ISO 13485:2003? You can t buy trust. BUILD IT through ISO 13485. Demonstrate your ability to supply medical devices through Quality Management System for Medical Devices - ISO 13485 ISO 13485 is
More informationCONSTITUTION SOUTHAMPTON CHILDREN & YOUNG PEOPLE S TRUST PARTNERSHIP
CONSTITUTION SOUTHAMPTON CHILDREN & YOUNG PEOPLE S TRUST PARTNERSHIP 1. AIMS To unify and co-ordinate services for children, young people and families in line with the Children Act 2004 To oversee the
More informationHearing aid dispenser approval process review Introduction Hearing aid dispenser data transfer... 6
Hearing aid dispenser approval process review 2010 11 Content 1.0 Introduction... 4 1.1 About this document... 4 1.2 Overview of the approval process... 4 2.0 Hearing aid dispenser data transfer... 6 2.1
More information15. Procuring, processing and transporting gametes and
15. Procuring, processing and transporting gametes and embryos Version 6.0 On this page: : Extracts from the HFE Act Directions HFEA guidance: Documented procedures: general Patient selection and procurement
More informationFrom the Deputy Chief Medical Officer / Chief Dental Officer Dr Anne Kilgallen / Simon Reid. Circular HSC (SQSD) (NICE NG30) 37/16
From the Deputy Chief Medical Officer / Chief Dental Officer Dr Anne Kilgallen / Simon Reid Circular HSC (SQSD) (NICE NG30) 37/16 Subject: NICE Public Health Guideline NG30 - Oral health promotion: general
More informationStudent Drug and Alcohol Policy
Student Drug and Alcohol Policy Purpose Central to all College activities are our Values of Spirituality, Respect, Integrity and Excellence, and our belief in empowering all young people to be their best
More informationExecutive Summary for Executive Licensing Panel 20 May Dr Kamal Ahuja. Follow-up inspection 14 April 2010
Summary for Licensing Panel 20 May 2010 Centre number 0011 Centre name The London Sperm Bank Person Responsible Dr Kamal Ahuja Background Follow-up inspection 14 April 2010 1. The London Sperm Bank underwent
More informationMHRA Pharmacovigilance Inspections: Prepare and Manage for Success
MHRA Pharmacovigilance Inspections: Prepare and Manage for Success Created and Presented by Miranda Dollen Vice President, Pharmacovigilance & EEA QPPV Mapi 2016, All Rights Reserved 2 Prepare and Manage
More informationTesting Railway Safety Critical Workers for Drugs and Alcohol
Rail Industry Standard RIS-8070-TOM Issue One Date December 2016 Critical Workers for Drugs and Alcohol Synopsis This document sets out common requirements for drugs and alcohol testing of staff carrying
More informationUALITY SYSTEMS STANDARDS
UALITY SYSTEMS STANDARDS VICTOR DORMAN-SMITH ABBOTT IRELAND Singapore 2002/05/17 BASIC STANDARDS ISO 9001, 2 & 3:1994 ISO 9001:2000 EN 46001, 2 :1993 Revised in 1996 ISO 13485 & 8:1996 DIS 13485:2002 =(ISO
More informationPersonal information, for purposes of this Policy, includes any information which relates to an identified or an identifiable person.
PART I: INTRODUCTION AND BACKGROUND Purpose This Data Protection Binding Corporate Rules Policy ( Policy ) establishes the approach of Fluor to compliance with European data protection law and specifically
More informationHow to change the legal classification of a medicine in New Zealand
How to change the legal classification of a medicine in New Zealand Guidance document Medsafe October 2017 Page 1 of 15 Contents Purpose and scope... 3 Definitions... 3 Background and legislative context...
More informationProcedural advice on the submission of variations for annual update of human influenza inactivated vaccines applications in the centralised procedure
1 2 3 4 5 6 7 8 9 14 April 2010 EMA/CHMP/BWP/99698/2007 Rev. 1 Committee for Medicinal Products for Human Use (CHMP) Procedural advice on the submission of variations for annual update of human influenza
More informationStandard Operating Procedure: Early Intervention in Psychosis Access Times
Corporate Standard Operating Procedure: Early Intervention in Psychosis Access Times Document Control Summary Status: New Version: V1.0 Date: Author/Owner: Rob Abell, Senior Performance Development Manager
More informationIAF Mandatory Document. Requirements for the Migration to ISO 45001:2018 from OHSAS 18001:2007 (IAF MD 21:2018)
IAF Mandatory Document Requirements for the Migration to ISO 45001:2018 from OHSAS 18001:2007 Issue 1 (IAF MD 21:2018) Issue 1 Requirements for the Migration to Page 2 of 12 The (IAF) facilitates trade
More informationFalls The Assessment, Prevention and Management of Patient Falls (Adult Services) 1.34
SECTION: 1 PATIENT CARE Including Physical Healthcare POLICY /PROCEDURE: 1.34 NATURE AND SCOPE: SUBJECT (Title): POLICY AND PROCEDURE - TRUST WIDE FALLS: THE ASSESSMENT, PREVENTION AND MANAGEMENT OF PATIENT
More informationmaking a referral for breast imaging Standard Operating Procedure
Document Control Title Reporting Radiographer Author Directorate Surgery Date Version Issued 0.1 May 2016 Status Draft Author s job title Reporting Radiographer Department Breast Imaging Comment / Changes
More information